# US 2024/0131168 A1 · Naphthalene ring-containing compound, pharmaceutical composition containing same, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0131168 A1
- Document ID: US20240131168A1
- Status: Published application
- Kind: A1
- Application number: 18/505,192
- Filed: 2023-11-09
- Published: 2024-04-25
- Earliest claimed: 2021-05-14
- Assignees: Jiangsu Yahong Meditech Co., Ltd.; Asieris Pharmaceuticals (Shanghai) Co., Ltd.
- Applicants: Jiangsu Yahong Meditech Co., Ltd.; Asieris Pharmaceuticals (Shanghai) Co., Ltd.
- Inventors: Liang WU; Yijun DENG; Zhenhua HE; Qiaoling SUN; Chen ZHOU; Tielin WANG
- Web page: https://patentgrep.com/patent/US20240131168A1

## CPC

- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61P 35/00: Antineoplastic agents
- C07C 69/94: of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
- C07C 205/38: the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
- C07C 217/90: the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
- C07C 235/42: having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C 317/22: with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Anaphthalene ring-containing compound, a pharmaceutical composition containing same, and the use thereof. A naphthalene ring-containing compound as represented by formula III, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof. The compound is new in structure and has a better activity on cancers.

## Claims

### Claim 1

A naphthalene ring-containing compound of formula III, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharmaceutically acceptable salt thereof,
wherein R1 is hydrogen, cyano, hydroxyl, or C1-C4 alkoxy;
X1 is —O—, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx1-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx1-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx1-1 is independently C1-C4 alkyl;
X2 is absent, —C(═O)—, C1-C6 alkylene, C2-C15 heteroalkylene, or C2-C15 heteroalkylene substituted by R21; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
Rx2-1 is independently C1-C4 alkyl;
X3 is absent, —C(═O)-Ph-, 5- to 6-membered heterocycloalkylene, 5- to 6-membered heteroarylene, 5- to 6-membered heterocycloalkylene substituted by Rx31, or 5- to 6-membered heteroarylene substituted by Rx3-2; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx3-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3; in the 5- to 6-membered heteroarylene and the 5- to 6-membered heteroarylene substituted by Rx3-2, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx3-1 and Rx3-2 are independently C1-C4 alkyl;
X4 is absent, C1-C10 alkylene, or C2-C15 heteroalkylene; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
X5 is absent, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx5-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx5-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx5-1 is independently C1-C4 alkyl;
X6 is absent, —O—, —NH—, —C(═O)—NH—, 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1; in the 5- to 6-membered heterocycloalkylene, the —C(═O)-5- to 6-membered heterocycloalkylene, and the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx6-1 is independently C1-C4 alkyl;
R2 is
R4 is —SO2—C1-C4 alkyl or
R3 is
or 3- to 6-membered heterocycloalkyl, Ra and Rb are independently hydrogen or C1-C4 alkyl; in the 3- to 6-membered heterocycloalkyl, the heteroatom is N, and the number of heteroatoms is 1 or 2.

### Claim 2 (depends on 1)

The naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1, wherein the naphthalene ring-containing compound of formula III is a naphthalene ring-containing compound of formula I or II:

### Claim 3 (depends on 2)

The naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 2, wherein the naphthalene ring-containing compound of formula III satisfies one or more than one of the following conditions:
(1) in R1, the C1-C4 alkoxy is methoxy, ethoxy, n-propoxy, or isopropoxy;
(2) in X1, in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx1-1, the heteroatom is N, and the number of heteroatoms is 1 or 2;
(3) in X1, the number of Rx1-1 is 1, 2, or 3;
(4) in Rx1-1, the C1-C4 alkyl is methyl or ethyl;
(5) in X2, the C1-C6 alkylene is methylene,
(6) in X2, the C2-C15 heteroalkylene is C4-C12 heteroalkylene;
(7) in X2, in the C2-C15 heteroalkylene, the heteroatom is O and/or N, and the number of heteroatoms is 1, 2, 3, 4, or 5;
(8) in X2, the C2-C15 heteroalkylene is linked to the other group through the carbon atom;
(9) in X3, in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx3-1, the heteroatom is N, and the number of heteroatoms is 1 or 2;
(10) in X3, the number of Rx3-1 is 1, 2, or 3;
(11) in Rx3-1, the C1-C4 alkyl is methyl or ethyl;
(12) in Rx3-2, the C1-C4 alkyl is methyl or ethyl;
(13) in X4, the C1-C10 alkylene is C1-C4 alkylene;
(14) in X4, the C2-C15 heteroalkylene is C2-C4 heteroalkylene;
(15) in X4, in the C2-C15 heteroalkylene, the heteroatom is O and/or N, and the number of heteroatoms is 1 or 2;
(16) in X5, in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx5-1, the heteroatom is N, and the number of heteroatoms is 1 or 2;
(17) in X5, the number of Rx5-1 is 1, 2, or 3;
(18) in Rx5-1, the C1-C4 alkyl is methyl or ethyl;
(19) in X6, in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the heteroatom is N, and the number of heteroatoms is 1 or 2;
(20) in X6, the number of Rx6-1 is 1, 2, or 3;
(21) in Rx6-1, the C1-C4 alkyl is methyl or ethyl;
(22) in X6, in the —C(═O)-5- to 6-membered heterocycloalkylene, the heteroatom is N, and the number of heteroatoms is 1 or 2;
(23) in X6, in the —C(═O)-5- to 6-membered heterocycloalkylene, the 5- to 6-membered heterocycloalkylene is piperidinylene or piperazinylene;
(24) X6 is linked to R2 through O or N;
(25) in Rx21, the C1-C4 alkyl is methyl or ethyl;
(26) in Ra, the C1-C4 alkyl is methyl or ethyl;
(27) in Rb, the C1-C4 alkyl is methyl or ethyl; and
(28) in R4, in the 3- to 6-membered heterocycloalkyl, the heteroatom is N, and the number of heteroatoms is 1.

### Claim 4 (depends on 2)

The naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 2, wherein the naphthalene ring-containing compound of formula III satisfies one or more than one of the following conditions:
(1) in X1, the 5- to 6-membered heterocycloalkylene is piperidinylene or piperazinylene;
(2) in X1, in the 5- to 6-membered heterocycloalkylene substituted by Rx1-1, the 5- to 6-membered heterocycloalkylene is piperidinylene or piperazinylene;
(3) in X3, the 5- to 6-membered heterocycloalkylene is piperidinylene or piperazinylene;
(4) in X3, in the 5- to 6-membered heterocycloalkylene substituted by Rx31, the 5- to 6-membered heterocycloalkylene is piperidinylene or piperazinylene;
(5) in X3, the 5- to 6-membered heteroarylene is triazolylene;
(6) in X4, the C2-C15 heteroalkylene is C2-C4 heteroalkylene in which the heteroatom is O and/or N and the number of heteroatoms is 1 or 2;
(7) in X3, in the 5- to 6-membered heteroarylene substituted by Rx3-2, the 5- to 6-membered heteroarylene is triazolylene;
(8) in X5, the 5- to 6-membered heterocycloalkylene is piperidinylene or piperazinylene;
(9) in X5, in the 5- to 6-membered heterocycloalkylene substituted by Rx5-1, the 5- to 6-membered heterocycloalkylene is piperidinylene or piperazinylene;
(10) in X5, the 5- to 6-membered heterocycloalkylene substituted by Rx5-1 is
(11) in X6, the 5- to 6-membered heterocycloalkylene is piperidinylene or piperazinylene;
(12) in X6, in the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the 5- to 6-membered heterocycloalkylene is piperidinylene or piperazinylene;
(13) in X6, the —C(═O)-5- to 6-membered heterocycloalkylene is
and
(14) in R3, the 3- to 6-membered heterocycloalkyl is

### Claim 5 (depends on 2)

The naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 2, wherein the naphthalene ring-containing compound of formula III satisfies one or more than one of the following conditions:
(1) in X1, the 5- to 6-membered heterocycloalkylene is
(2) in X1, in the 5- to 6-membered heterocycloalkylene substituted by Rx1-1, the 5- to 6-membered heterocycloalkylene is
(3) in X3, the 5- to 6-membered heterocycloalkylene is
(4) in X3, in the 5- to 6-membered heterocycloalkylene substituted by Rx3-1, the 5- to 6-membered heterocycloalkylene is
(5) in X3, the 5- to 6-membered heteroarylene is
(6) in X3, in the 5- to 6-membered heteroarylene substituted by Rx3-2, the 5- to 6-membered heteroarylene is
(7) in X4, the C1-C10 alkylene is methylene or
(8) in X4, the C2-C15 heteroalkylene is
(9) in X5, the 5- to 6-membered heterocycloalkylene is
(10) in X5, in the 5- to 6-membered heterocycloalkylene substituted by Rx5-1, the 5- to 6-membered heterocycloalkylene is
(11) in X6, the 5- to 6-membered heterocycloalkylene is
(12) in X6, in the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the 5- to 6-membered heterocycloalkylene is
(13) in X6, in the —C(═O)-5- to 6-membered heterocycloalkylene, the 5- to 6-membered heterocycloalkylene is
(14) in X2, the C2-C15 heteroalkylene is any one of the following structures:
(15) the chiral carbon atom in R2 is in S configuration and R configuration; and
(16) the chiral carbon atom in R1, X1, X2, X3, X4, X5, and X6 is in S configuration and R configuration.

### Claim 6 (depends on 5)

The naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 5, wherein the naphthalene ring-containing compound of formula III or the pharmaceutically acceptable salt thereof satisfies one or more than one of the following conditions:
(1) X2 is —C(═O)— or C1-C6 alkylene;
(2) X6 is 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1;
(3) R2 is
(4) X1 is —O—; and
(5) X3, X4, and X5 are absent.

### Claim 7 (depends on 5)

The naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 5, wherein the naphthalene ring-containing compound of formula III or the pharmaceutically acceptable salt thereof satisfies one or more than one of the following conditions:
(1) X1 is —O— or
(2) X2 is absent, —C(═O)—, methylene
(3) X3 is absent,
(4) X4 is absent, methylene,
(5) X5 is absent or
(6) X6 is absent, —O—, —NH—, —C(═O)—NH—,
(7) R2 is
(8) the pharmaceutically acceptable salt is hydrochloride; and
(9) R3 is

### Claim 8 (depends on 2)

The naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 2, wherein the naphthalene ring-containing compound of formula III is defined as any one of the following schemes:
scheme 1: R1 is hydroxyl, X3, X4, and X5 are absent, X1 is —O—, X2 is C1-C6 alkylene, X6 is 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1, and R2 is
scheme 2: R1 is hydroxyl;
X1 is —O—;
X2 is C1-C6 alkylene, C2-C15 heteroalkylene, or C2-C15 heteroalkylene substituted by Rx2-1;
Rx2-1 is independently C1-C4 alkyl;
X3 is absent, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx3-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx3-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
X4 is absent or C2-C15 heteroalkylene; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
X5 is absent;
X6 is 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1; in the 5- to 6-membered heterocycloalkylene, the —C(═O)-5- to 6-membered heterocycloalkylene, and the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
R2 is
scheme 3: R1 is hydroxyl;
X1 is —O—;
X2 is C1-C6 alkylene, C2-C15 heteroalkylene, or C2-C15 heteroalkylene substituted by Rx2-1; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
Rx2-1 is independently C1-C4 alkyl;
X3 is absent, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx3-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx3-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
X4 is absent, —C(═O)-Ph-, or C2-C15 heteroalkylene; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
X5 is absent, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx5-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx5-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
X6 is absent, 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1; in the 5- to 6-membered heterocycloalkylene, the —C(═O)-5- to 6-membered heterocycloalkylene, and the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
R2 is
scheme 4: R1 is hydroxyl;
X1 is —O—;
X2 is C1-C6 alkylene;
X3 is absent; X4 is absent; X5 is absent;
X6 is 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1; in the 5- to 6-membered heterocycloalkylene, the —C(═O)-5- to 6-membered heterocycloalkylene, and the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
R2 is
scheme 5: X1 is —O—;
X2 is C1-C6 alkylene, C2-C15 heteroalkylene, or C2-C15 heteroalkylene substituted by Rx2-1; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
Rx2-1 is independently C1-C4 alkyl;
X3 is absent or —C(═O)-Ph-;
X4 is absent or C1-C10 alkylene;
X5 is absent, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx5-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx5-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
X6 is —O—, —NH—, 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1; in the 5- to 6-membered heterocycloalkylene, the —C(═O)-5- to 6-membered heterocycloalkylene, and the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
R2 is
scheme 6: R1 is hydroxyl or C1-C4 alkoxy;
X1 is —O—;
X2 is C1-C6 alkylene;
X3 is absent; X4 is absent; X5 is absent;
X6 is 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1; in the 5- to 6-membered heterocycloalkylene, the —C(═O)-5- to 6-membered heterocycloalkylene, and the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
R2 is
scheme 7: R1 is hydroxyl;
X1 is —O—;
X2 is C1-C6 alkylene or C2-C15 heteroalkylene;
X3 is absent, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx3-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx3-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
X4 is absent or C2-C15 heteroalkylene; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
X5 is absent;
X6 is 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1; in the 5- to 6-membered heterocycloalkylene, the —C(═O)-5- to 6-membered heterocycloalkylene, and the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
R2 is
scheme 8: R1 is hydroxyl;
X1 is —O—;
X2 is C1-C6 alkylene, C2-C15 heteroalkylene, or C2-C15 heteroalkylene substituted by Rx2-1; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
Rx2-1 is independently C1-C4 alkyl;
X3 is absent, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx3-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx3-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
X4 is absent, —C(═O)-Ph-, or C2-C15 heteroalkylene; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
X5 is absent, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx5-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx5-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
X6 is absent, 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1; in the 5- to 6-membered heterocycloalkylene, the —C(═O)-5- to 6-membered heterocycloalkylene, and the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
R2 is
scheme 9: R1 is cyano, hydroxyl, or C1-C4 alkoxy;
X1 is —O—, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx1-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx1-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx1-1 is independently C1-C4 alkyl;
X2 is C1-C6 alkylene or C2-C15 heteroalkylene; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
X3 is absent, —C(═O)-Ph-, 5- to 6-membered heterocycloalkylene, 5- to 6-membered heteroarylene, 5- to 6-membered heterocycloalkylene substituted by Rx31, or 5- to 6-membered heteroarylene substituted by Rx3-2; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx3-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3; in the 5- to 6-membered heteroarylene and the 5- to 6-membered heteroarylene substituted by Rx3-2, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx3-1 and Rx3-2 are independently C1-C4 alkyl;
X4 is absent, C1-C10 alkylene, or C2-C15 heteroalkylene; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
X5 is absent, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx5-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx5-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx5-1 is independently C1-C4 alkyl;
X6 is absent, —O—, —NH—, —C(═O)—NH—, 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1; in the 5- to 6-membered heterocycloalkylene, the —C(═O)-5- to 6-membered heterocycloalkylene, and the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx6-1 is independently C1-C4 alkyl;
R2 is
scheme 10: in the naphthalene ring-containing compound of formula I,
wherein R1 is hydrogen, cyano, hydroxyl, or C1-C4 alkoxy;
X1 is —O—, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx1-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx1-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx1-1 is independently C1-C4 alkyl;
X2 is C1-C6 alkylene or C2-C15 heteroalkylene; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
X3 is absent, —C(═O)-Ph-, 5- to 6-membered heterocycloalkylene, 5- to 6-membered heteroarylene, 5- to 6-membered heterocycloalkylene substituted by Rx3-1, or 5- to 6-membered heteroarylene substituted by Rx3-2; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx3-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3; in the 5- to 6-membered heteroarylene and the 5- to 6-membered heteroarylene substituted by Rx3-2, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx3-1 and Rx3-2 are independently C1-C4 alkyl;
X4 is absent, C1-C10 alkylene, or C2-C15 heteroalkylene; in the C2-C15 heteroalkylene, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, 3, 4, 5, 6, 7, 8, or 9;
X5 is absent, 5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx5-1; in the 5- to 6-membered heterocycloalkylene and the 5- to 6-membered heterocycloalkylene substituted by Rx5-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx5-1 is independently C1-C4 alkyl;
X6 is absent, —O—, —NH—, —C(═O)—NH—, 5- to 6-membered heterocycloalkylene, —C(═O)-5- to 6-membered heterocycloalkylene, or 5- to 6-membered heterocycloalkylene substituted by Rx6-1; in the 5- to 6-membered heterocycloalkylene, the —C(═O)-5- to 6-membered heterocycloalkylene, and the 5- to 6-membered heterocycloalkylene substituted by Rx6-1, the heteroatom is one or more than one of O, S, and N, and the number of heteroatoms is 1, 2, or 3;
Rx6-1 is independently C1-C4 alkyl;
R2 is
scheme 11:
in the naphthalene ring-containing compound of II,
R1 is hydrogen or hydroxyl;
X1 is —O—;
X2 is —C(═O)— or C1-C6 alkylene;
X3 is absent;
X4 is absent;
X5 is absent;
X6 is 5- to 6-membered heterocycloalkylene; in the 5- to 6-membered heterocycloalkylene, the heteroatom is N, and the number of heteroatoms is 1, 2, or 3;
R2 is
R3 is
or 3- to 6-membered heterocycloalkyl, Ra and Rb are independently hydrogen or C1-C4 alkyl; the 3- to 6-membered heterocycloalkyl is linked to carbonyl through N; in the 3- to 6-membered heterocycloalkyl, the heteroatom is N, and the number of heteroatoms is 1 or 2.

### Claim 9 (depends on 1)

The naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1, wherein
—X1—X2—X3—X4—X5—X6— is

### Claim 10 (depends on 1)

The naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1, wherein in the naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof, the naphthalene ring-containing compound of formula III is as represented by any one of the following structures:
Com-
pound
No.
Structural formula
D1
D2
D57
D3
D4
D5
D58
D6
D7
D8
D9
D10
D11
D12
D13
D59
D14
D15
D16
D17
D18
D19
D20
D21
D22
D23
D24
D25
D26
D27
D28
D29
D30
D60
D31
D32
D33
D34
D35
D36
D37
D38
D39
D40
D41
D42
D43
D44
D45
D46
D47
D48
D49
D50
D51
D52
D61
D53
D62
D63
D54
D55
D56
D64
D65
D66
D67
D68
D69
or, the pharmaceutically acceptable salt of the naphthalene ring-containing compound of formula III is

### Claim 11 (depends on 1)

A pharmaceutical composition consisting of substance B and a pharmaceutical excipient;
the substance B is the naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt according to claim 1.

### Claim 12 (depends on 1)

A method for treating cancer in a subject in need thereof, comprising administering substance B to the subject;
the substance B is the naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 1.

### Claim 13 (depends on 1)

A naphthalene ring-containing compound of formula IV or a salt thereof,
wherein R4 is —SO2—C1-C4 alkyl or
R3 is
X1 is —O—;
X2, X3, X4, X5, and X6 are as described in claim 1; X2, X3, X4, X5, and X6 are not simultaneously absent;
R2 is hydrogen,
R1 is hydrogen, benzyl, hydroxyl, or C1-C4 alkoxy.

### Claim 14

A compound or a salt thereof, which has any one of the following structures:

### Claim 15 (depends on 2)

The naphthalene ring-containing compound of formula III, the pharmaceutically acceptable salt thereof, the solvate thereof, or the solvate of the pharmaceutically acceptable salt thereof according to claim 2, wherein the naphthalene ring-containing compound of formula III satisfies one or more than one of the following conditions:
(1) in X1, the 5- to 6-membered heterocycloalkylene substituted by Rx1-1 is
(2) in X3, the 5- to 6-membered heterocycloalkylene substituted by Rx3-1 is
(3) in X6 the 5- to 6-membered heterocycloalkylene substituted by Rx6-1 is
(4) the chiral carbon atom in R2 is in S configuration and R configuration, and the ratio of S configuration to R configuration is 1:1; and
(5) the chiral carbon atom in R1, X1, X2, X3, X4, X5, and X6 is in S configuration and R configuration, and the ratio of S configuration to R configuration is 1:1.

### Claim 16 (depends on 12)

The method according to claim 12, wherein the cancer is breast cancer.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the breast cancer is Luminal A breast cancer, Luminal B breast cancer, HER2-positive breast cancer, or triple-negative breast cancer.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the Luminal A breast cancer is non-drug-resistant and non-mutated Luminal Abreast cancer, drug-resistant and non-mutated Luminal A breast cancer, or drug-resistant and mutated Luminal Abreast cancer.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the drug-resistant and non-mutated Luminal Abreast cancer is tamoxifen-resistant and non-mutated Luminal Abreast cancer;
or, the drug-resistant and mutated Luminal Abreast cancer is ERD538G-mutated Luminal A breast cancer;
or, the drug-resistant and mutated Luminal Abreast cancer is ERY537S-mutated Luminal A breast cancer.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the drug-resistant and mutated Luminal A breast cancer is tamoxifen- or fulvestrant-resistant and ERD538G-mutated Luminal A breast cancer;
or, the drug-resistant and mutated Luminal A breast cancer is tamoxifen- or fulvestrant-resistant and ERY537S-mutated Luminal Abreast cancer.
